HALO vs. SNY: Halozyme Therapeutics vs. Sanofi Stock Comparison

Company Profile

Halozyme Therapeutics (HALO) and Sanofi (SNY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but HALO is classified in Biotechnology while SNY is classified in Pharmaceuticals.

Halozyme Therapeutics (HALO) trades as ordinary local shares, while Sanofi (SNY) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Halozyme Therapeutics (HALO) at 216.38% clears its industry range for ROE, a sharper capital-efficiency signal than Sanofi (SNY) at 5.72%, which is closer to a typical peer reading.

Halozyme Therapeutics (HALO) at 26.93% keeps the most of each sales dollar — above its industry’s net margin range — and Sanofi (SNY) at 8.20% also retains a top-quartile share.

Both Halozyme Therapeutics (HALO) at 59.84% and Sanofi (SNY) at 30.89% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Halozyme Therapeutics (HALO) at 37.55% and Sanofi (SNY) at 5.49% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Both Halozyme Therapeutics (HALO) at -25.36% and Sanofi (SNY) at 39.43% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Growth Metrics

Financial Strength

Halozyme Therapeutics (HALO) at 3.88 keeps current ratio within its industry’s typical mid-range, while Sanofi (SNY) at 1.12 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for SNY.

Only one side’s leverage can be read here: Sanofi (SNY) carries debt-to-equity ratio of 0.27 against its industry range, while Halozyme Therapeutics (HALO) reports no figure this period.

Financial Strength Metrics

Dividends

Neither Halozyme Therapeutics (HALO) nor Sanofi (SNY) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Sanofi (SNY) reports payout ratio above 100% at 119.86%, meaning dividends exceeded current-period earnings; Halozyme Therapeutics (HALO) pays no dividend (payout 0.00%).

Dividend Metrics

Valuation

Both Halozyme Therapeutics (HALO) at 25.91 and Sanofi (SNY) at 23.40 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

Sanofi (SNY) at 2.21 sits in the cheaper P/S ratio quartile while Halozyme Therapeutics (HALO) at 6.55 prices around its industry’s middle — SNY costs less per dollar of sales, though read it alongside growth and margins.

Halozyme Therapeutics (HALO) reports a negative P/B ratio of -213.67, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Sanofi (SNY) reports 1.38, ranking against industry peers normally.

Valuation Metrics